‹ All questions

Medtronic vs Solventum: which stock is doing better?

Medtronic and Solventum are business rivals. Where they compete: wound management, surgical products, and health IT solutions. Here is how the two stocks, and the businesses behind them, compare over the past year.

Updated Oct 9, 2026

47
SOLV P3

SOLV ahead

On Stox’s P3 score, which combines market beat, staying power and business growth, Solventum rates 47 and Medtronic 35. Over the past year Medtronic is −10% and Solventum +21%, against +16% for the S&P 500. Medtronic has grown revenue faster, +7% against −1%. Medtronic swings less, about 2.2% on a typical day against 2.6%. By type, Medtronic is a Falling Knife and Solventum a Faith Trade.

MDT P3 35SOLV P3 471Y: MDT −10%, SOLV +21%

The past year

MDT against SOLV, each set to $100 a year ago. Select a measure in the table below to chart it for both.

MDT against SOLV, past year
$100 a year ago. MDT −10%, SOLV +21%.
80100120NovDecJanFebMarAprMayJunJulAugSepOct
MDTSOLV

MDT and SOLV side by side

Ahead marks the stronger reading on each line; for the typical day and the deepest fall it marks the steadier stock. Select a row with a chart to see both over the year.

MeasureMDTSOLVAhead
Past 3 months
Share price change
+6%+13%SOLV
Past month
Share price change
−3%−0%SOLV
Revenue growth
Past four quarters against the year before
+7%−1%MDT
Operating margin
Operating profit as a share of revenue, past four quarters
18%26%SOLV
Deepest fall
From a high, past year
−30%−28%SOLV, held up
Market value
What the market values the company at
$113.3B$15.1B
Type
Its Stox Atlas type
Falling KnifeFaith Trade
Group
Stocks it moves with
Health care–

How to read this page

How it’s measured. Scores from Stox rank each stock against about 1,200 large US stocks and funds, where 100 is best; P3 combines market beat, staying power and business growth. Returns are share-price changes. The typical day is the average true range over 14 days as a share of the price, averaged over the past year.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and curated rivals from Stox.

A higher score describes a stronger past year, not what comes next.

Rivals are chosen by the markets the two businesses compete in, not by sector labels.

For financial statements, valuation and news, see MDT and SOLV on Stox.

This page is information, not investment advice. About our data and methods ›

More head-to-heads

See all questions ›